Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials | News
Search Refinements

Clinical Trials News

View news from other Pharmaceutical sectors:
16-30 of 4127 results
LabCorp to acquire clinical trials firm Chiltern for $1.2bn
By PBR Staff Writer
LabCorp has agreed to acquire specialty contract research organization (CRO) Chiltern for nearly $1.2bn in an all-cash deal to expand its oncology offerings.
Contract Research & Services > Clinical Trials > News
AstraZeneca's lung cancer immunotherapy trial fails to meet primary endpoint
By PBR Staff Writer
AstraZeneca’s Imfinzi (durvalumab) in combination with tremelimumab failed to improve progression-free survival (PFS) significantly in a phase 3 trial in previously untreated patients having advanced lung cancer.
Contract Research & Services > Clinical Trials > News
Merck’s Keytruda fails to improve survival in phase 3 head and neck cancer trial
By PBR Staff Writer
Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) failed to improve overall survival (OS) in a pivotal phase 3 trial in head and neck squamous cell carcinoma (HNSCC) patients compared to standard treatment.
Contract Research & Services > Clinical Trials > News
Bayer's phase 2 clinical trial of monotherapy for second-line mesothelioma fails
Bayer’s phase 2 clinical study examining anetumab ravtansine as monotherapy in patients with recurrent malignant pleural mesothelioma did not meet the primary endpoint of progression-free survival.
Contract Research & Services > Clinical Trials > News
Brainstorm secures $16m grant for phase 3 trial of NurOwn in ALS
The California Institute for Regenerative Medicine (CIRM) has awarded a grant of $16m to Brainstorm Cell Therapeutics to support a phase 3 study of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS).
Contract Research & Services > Clinical Trials > News
Alzheimer’s drug reduces hallmark inflammation related to metabolic syndrome by 25%
An existing Alzheimer’s medication has been found to cut inflammation and insulin resistance in patients with metabolic syndrome, as per new clinical trial results put up by scientists at Northwell Health’s The Feinstein Institute for Medical Research.
Contract Research & Services > Clinical Trials > News
Incyte launches phase 3 trial of Itacitinib for acute graft-versus-host disease
Incyte reported that the first patient has been treated in a phase 3 trial dubbed GRAVITAS-301 for the first-line treatment of patients with acute graft-versus-host disease (GVHD).
Contract Research & Services > Clinical Trials > News
Tiziana launches phase IIa trial of milciclib in HCC patients
Tiziana Life Sciences has started enrolling of patients in its phase IIa clinical trial with cyclin-dependent kinases (CDKs) inhibitor milciclib in patients with refractory hepatocellular carcinoma (HCC).
Contract Research & Services > Clinical Trials > News
Vertex reports positive data from cystic fibrosis trials
Vertex Pharmaceuticals has reported positive data from Phase 1 and Phase 2 trials of three different triple combination regimens in cystic fibrosis (CF) patients who have one F508del mutation and one minimal function mutation (F508del/Min).
Contract Research & Services > Clinical Trials > News
PureTech Health presents inflammation drug research data at Boston Conference
PureTech Health has presented data for product candidate ALV-107 showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose (ALV-107 16 mg/kg, conventional lidocaine 16 mg/kg), in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
Contract Research & Services > Clinical Trials > News
Amgen’s Kyprolis regimen improves survival rate phase 3 myeloma trial
By PBR Staff Writer
Amgen has reported that Kyprolis (Carfilzomib) in combination with lenalidomide and dexamethasone significantly improved the overall survival in a phase 3 trial in multiple myeloma patients whose disease had relapsed.
Contract Research & Services > Clinical Trials > News
Amicus plans to submit NDA to FDA for migalastat for fabry disease
Amicus Therapeutics has revealed its plans to file a new drug application (NDA) with the US FDA for the oral precision medicine migalastat for Fabry disease in the fourth quarter of the year.
Contract Research & Services > Clinical Trials > News
Elite reports topline results from bioequivalence fed study for SequestOx
Elite Pharmaceuticals has reported topline results from a pivotal bioequivalence fed study for SequestOx.
Contract Research & Services > Clinical Trials > News
Alnylam, Sanofi begin clinical trial program of hemophilia treatment fitusiran
By PBR Staff Writer
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced Atlas Phase 3 clinical program for hemophilia treatment, fitusiran.
Contract Research & Services > Clinical Trials > News
Entasis, GARP to start phase 3 trials of drug-resistant gonorrhea antibiotic
By PBR Staff Writer
Entasis Therapeutics and Global Antibiotic Research and Development Partnership (GARDP) will initiate pivotal trials of oral antibiotic zoliflodacin (ETX0914) being developed to treat drug-resistant gonorrhea.
Contract Research & Services > Clinical Trials > News
16-30 of 4127 results